Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia

Table 1 Demographic details of patients

	Control	AD–MB	AD+MB	VaD
N	21	25	25	21
Sex, female:male	10:11	10:15	11:14	7:15
MMSE^a	28.5 ± 1.4	21.7 ± 4.3	18.44 ± 5.5	23.50 ± 3.9
Age	65.9 ± 6.1	67.8 ± 6.3	67 ± 7.7	68.6 ± 6.6
Aβ42 (pg/ml)	803 (1057–675)	500 (612–423)	408 (491–304)	606 (868–424)
tTau (pg/ml)	313 (442–240)	615 (743–430)	567 (784–396)	361 (498–196)
pTau (pg/ml)	53 (73–46.50)	85 (109–66.5)	89 (105–68.5)	50 (65–31)
VEGF (pg/ml)	2.7 (3.4–2.3)	2.8 (3.6–2.4)	2.7 (3.2–2.5)	3.1 (3.9–2.6)

MMSE scores and age presented as mean ± standard deviation. Cerebrospinal fluid biomarkers presented as median (interquartile range)
Aβ42 beta-amyloid, AD–MD Alzheimer’s disease without microbleeds, AD+MB Alzheimer’s disease with microbleeds, MMSE Mini-Mental State Examination, pTau phosphorylated tau, tTau total tau, VaD vascular dementia, VEGF vascular endothelial growth factor
^aA 30-point questionnaire to assess cognitive health

ISSN: 1758-9193